Long-term treatment of Nicotinamide mononucleotide improved age-related diminished ovary reserve through enhancing the mitophagy level of granulosa cells in mice
Pan Huang et al. · The Journal of Nutritional Biochemistry · 2022
DesignPreclinical long-term intervention study across female-mouse age groups with ovarian histology and granulosa-cell mitophagy analyses
PopulationFemale ICR mice, including 40-week-old mice treated for 20 weeks
SampleMultiple age and treatment groups; see publication
InterventionLong-term NMN administration for 20 weeks in aged female mice
EndpointsEstrous-cycle measures; Ovarian follicle counts; Endocrine function; Inflammation; Granulosa-cell mitochondrial function and mitophagy; Ovarian reserve
What the publication reported
This study tested long-term NMN administration in aging female mice and focused on ovarian reserve and mitochondrial quality-control pathways.
Compared with aged controls, NMN-treated mice showed more follicles at several developmental stages, changes in endocrine and inflammatory measures, and enhanced mitophagy-related signals in granulosa cells.
These are preclinical reproductive-aging findings and do not demonstrate that NMN preserves ovarian reserve or fertility in women.
Key findings
Long-term NMN altered estrous-cycle and endocrine measures in aged mice.
Follicle counts at multiple developmental stages were higher in treated aged mice.
Granulosa-cell mitochondrial and mitophagy-related measures changed.
The study linked ovarian-aging phenotypes with NAD-related mitochondrial mechanisms.
What it cannot establish
Mouse study only.
Twenty-week exposure in mice cannot be directly translated to human reproductive aging.
Follicle counts and cellular mechanisms are not equivalent to live-birth or pregnancy outcomes.
No human ovarian-reserve trial was performed.
HealthspanX claim boundary: This study does not establish that NMN preserves ovarian reserve, fertility or reproductive lifespan in women.
